Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II

NCT05055258 is registered in ClinicalTrials.gov with KalVista Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT05055258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05055258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
November 18, 2021
Completion date
October 27, 2022
Enrollment
33 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

angioedema, hereditary, types i and ii